Efficacy of venetoclax combined with azacitidine in the treatment of patients with newly diagnosed unfit acute myeloid leukemia
10.3969/j.issn.1673-9701.2024.01.018
- VernacularTitle:维奈克拉联合阿扎胞苷治疗初诊不适合强化疗的急性髓系白血病患者的疗效观察
- Author:
Menghong WEI
1
;
Hailong XIA
1
Author Information
1. Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui, China
- Publication Type:Journal Article
- Keywords:
Venetoclax;
Azacitidine;
Acute myeloid leukemia;
Overall survival;
Adverse events
- From:
China Modern Doctor
2024;62(1):74-77
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of VA regimen(venetoclax + azacitidine)in the treatment of patients with newly diagnosed unfit acute myeloid leukemia(AML).Methods From April 2021 to February 2023,55 unfit AML patients who were treated with VA regimen in the First Affiliated Hospital of Anhui Medical University were retrospectively analysed.The therapeutic efficacy and safety of VA regimen were evaluated.Results The median treatment courses of AML patients was 3(1-10),and complete response(CR)/CR with incomplete blood count recovery(CRi)rate was 78.2%and minimal residual(MRD)negative conversion rate was 61.8%after the first treatment course.CR/CRi rate and MRD negative conversion rate increased gradually with the increase of treatment course.Patients with IDH1/IDH2,NPM1,ASXL1 mutations and without TP53 mutations responded well to the VA regimen.The median follow-up time was 9.1(1.2-24.0)months.39 patients survived and 16 patients died.The median overall survival(OS)was 17.4 months.Patients with CR/CRi had significantly longer OS duration than patients with partial response or non-response(P<0.001).Almost all patients had different degrees of anemia,thrombocytopenia,leukopenia.In terms of non-hematological adverse events,infection was the most common.Conclusion The VA regimen achieved a higher treatment response rate in newly diagnosed unfit AML patients,and partial response patients could quickly obtain negative MRD.IDH1/IDH2,ASXL1,NPM1,TP53 mutations may be the predictors of patient outcomes.
